Shire has agreed to sell a portfolio of non-core products to Almirall for $213 million in cash in order to pursue its new market strategy. The portfolio includes the dermatology products, Solaraze for the treatment of common skin lesions caused by sun damage, Vaniqa, a topical prescription medicine for treating unwanted facial hair, and six other non-promoted products across a range of indications, which are Shire sells in the UK, France, Germany, Italy, Spain and Ireland. Shire’s new...